MHRA approves for Epidyolex® (cannabidiol) for TSC seizure treatment
GW Pharmaceuticals received approval for Epidyolex®(cannabidiol) for the treatment of seizures linked to tuberous sclerosis complex (TSC) in the UK.
August 13, 2021
by europeanpharmaceuticalreview
UK approval for Epidyolex to treat seizures from tuberous sclerosis
Jazz Pharmaceuticals subsidiary GW Pharmaceuticals has received approval from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for its cannabidiol Epidyolex as an adjunctive treatment of seizures associated with tuberous sclerosis ...
August 11, 2021
by pharmatimes
GW Pharma’s Epidyolex scores new EU indication
GW Pharmaceuticals’ Epidyolex has received approval from the European Commission (EC) for the treatment of seizures associated with tuberous sclerosis complex (TSC) – its third indication in Europe.
April 22, 2021
by pharmatimes
GW Pharmaceuticals Receives European Commission Approval for EPIDYOLEX® (cannabidiol) for the Treatment of Seizures Associated with Tuberous Sclerosis Complex
GW Pharmaceuticals plc, a world leader in discovering, developing and delivering regulatory approved cannabis-based medicines, today announces that the European Commission (EC) has approved the Type II variation application for EPIDYOLEX® ...
April 21, 2021
by americanpharmaceuticalreview
GW Receives Positive CHMP Opinion for EPIDYOLEX for TSC Seizures
GW Pharmaceuticals announced the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion on the Company’s Type II variation application for EPIDYOLEX® (cannabidiol) as an adjunctive ...
March 4, 2021
by americanpharmaceuticalreview
FDA approves Epidyolex for treatment of tuberous sclerosis complex-associated seizures
Epidyolex, a cannabidiol oral solution, has been given approval by the FDA to treat seizures associated with tuberous sclerosis complex (TSC).
August 4, 2020
by europeanpharmaceuticalreview
Epidyolex (cannabidiol) reclassified as Schedule 5 in UK, relaxing control over drug
GW Pharmaceuticals’s Epidyolex (cannabidiol) has been changed from a Schedule 2 drug to a Schedule 5 drug, making it exempt from virtually all controlled drug requirements.
June 28, 2020
by europeanpharmaceuticalreview
Key European committee backs GW's Epidyolex, Bayer's Vitrakvi and more
In a busy meeting this week, experts with the European Medicines Agency's Committee for Medicinal Products for Human Use endorsed four new drugs, a Mylan generic, and numerous new indications for already-marketed meds.
July 28, 2019
by fiercepharma